Wellington Management Group’s ADC Therapeutics ADCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$866K Buy
231,064
+18,149
+9% +$71.6K ﹤0.01% 1701
2025
Q4
$752K Sell
212,915
-37,169
-15% -$151K ﹤0.01% 1765
2025
Q3
$1M Buy
+250,084
New +$788K ﹤0.01% 1778
2025
Q1
Sell
-253,342
Closed -$504K 1935
2024
Q4
$504K Buy
253,342
+84,785
+50% +$222K ﹤0.01% 1831
2024
Q3
$531K Buy
+168,557
New +$532K ﹤0.01% 1810

Other funds holding ADCT

Wellington Management Group's ADCT Position: Q1 2026 in Review

Wellington Management Group increased its ADC Therapeutics (ADCT) stake by 8.5% in Q1 2026, buying an estimated $71.6K and bringing the position to 231,064 shares worth $866K. The position accounts for ﹤0.01% of the portfolio, ranked #1701.

Wellington Management Group first reported a position in ADCT in Q3 2024 and has held it in 5 quarters since. The position peaked at $1M in Q3 2025. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Wellington Management Group held 231,064 shares of ADC Therapeutics worth $866K as of Q1 2026.
  • Wellington Management Group bought 18,149 ADC Therapeutics shares in Q1 2026, an estimated $71.6K.
  • ADC Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q1 2026, its #1701 holding.
  • Wellington Management Group first reported a position in ADC Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Wellington Management Group's ADC Therapeutics position peaked at $1M in Q3 2025.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Wellington Management Group's 13F filing for Q1 2026, filed 15 May 2026.